EXACT SCIENCES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 58.85 USD | +0.10% |
|
-3.46% | -20.45% |
| Apr. 17 | Exact Sciences Corporation announced that it has received $266.75 million in funding | CI |
| Apr. 15 | Sector Update: Health Care Stocks Advance Premarket Monday | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 13,616 | 21,070 | 13,412 | 8,797 | 13,379 | 10,820 | - | - |
| Enterprise Value (EV) 1 | 14,120 | 20,573 | 14,561 | 10,401 | 14,916 | 12,323 | 11,903 | 11,498 |
| P/E ratio | -145 x | -23.6 x | -22.4 x | -14 x | -65.5 x | -67 x | 2,257 x | 69 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 15.5 x | 14.1 x | 7.59 x | 4.22 x | 5.35 x | 3.82 x | 3.35 x | 2.97 x |
| EV / Revenue | 16.1 x | 13.8 x | 8.24 x | 4.99 x | 5.97 x | 4.35 x | 3.69 x | 3.16 x |
| EV / EBITDA | -117 x | 789 x | -77.4 x | -72.5 x | 68.2 x | 36.9 x | 22.8 x | 16.4 x |
| EV / FCF | -49.2 x | 285 x | -61.2 x | -23.7 x | 467 x | 85.7 x | 35.8 x | 21.6 x |
| FCF Yield | -2.03% | 0.35% | -1.63% | -4.21% | 0.21% | 1.17% | 2.79% | 4.64% |
| Price to Book | 5.97 x | 7.09 x | 3.94 x | 2.87 x | 4.27 x | 3.31 x | 3.05 x | 2.72 x |
| Nbr of stocks (in thousands) | 147,232 | 159,030 | 172,319 | 177,684 | 180,850 | 183,850 | - | - |
| Reference price 2 | 92.48 | 132.5 | 77.83 | 49.51 | 73.98 | 58.85 | 58.85 | 58.85 |
| Announcement Date | 2/11/20 | 2/16/21 | 2/22/22 | 2/21/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 876.3 | 1,491 | 1,767 | 2,084 | 2,500 | 2,833 | 3,225 | 3,642 |
| EBITDA 1 | -120.7 | 26.08 | -188.1 | -143.4 | 218.8 | 333.8 | 521.9 | 702.4 |
| EBIT 1 | -170.9 | -137.3 | -599.4 | -580 | -259.1 | -173.5 | -1.445 | 151.4 |
| Operating Margin | -19.51% | -9.21% | -33.92% | -27.83% | -10.36% | -6.13% | -0.04% | 4.16% |
| Earnings before Tax (EBT) 1 | -268.9 | -857.1 | -842.5 | -632.6 | -201.7 | -161.9 | 12.21 | 187 |
| Net income 1 | -83.99 | -848.5 | -595.6 | -623.5 | -204.1 | -160.5 | 6.14 | 164.4 |
| Net margin | -9.59% | -56.9% | -33.71% | -29.91% | -8.17% | -5.67% | 0.19% | 4.52% |
| EPS 2 | -0.6400 | -5.610 | -3.480 | -3.540 | -1.130 | -0.8778 | 0.0261 | 0.8525 |
| Free Cash Flow 1 | -286.8 | 72.13 | -238 | -438 | 31.93 | 143.8 | 332.1 | 533.1 |
| FCF margin | -32.73% | 4.84% | -13.47% | -21.02% | 1.28% | 5.08% | 10.3% | 14.64% |
| FCF Conversion (EBITDA) | - | 276.6% | - | - | 14.59% | 43.09% | 63.62% | 75.89% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 5,408.3% | 324.18% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/11/20 | 2/16/21 | 2/22/22 | 2/21/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 456.4 | 473.8 | 486.6 | 521.6 | 523.1 | 553 | 602.4 | 622.1 | 628.3 | 646.9 | 628.6 | 700.1 | 733.1 | 773 | 727.2 |
| EBITDA 1 | -16.27 | -122.2 | -89.82 | -45.77 | -13.04 | 4.934 | 45.91 | 66.85 | 56.28 | 49.71 | 30.28 | 77.71 | 102.9 | 123.4 | 96.28 |
| EBIT 1 | -121.6 | -222.2 | -202.9 | -162.1 | -119.9 | -95.34 | -65.73 | -72.1 | -68.07 | -70.93 | -95.2 | -51.21 | -24.51 | -6.773 | -46.4 |
| Operating Margin | -26.64% | -46.9% | -41.71% | -31.08% | -22.93% | -17.24% | -10.91% | -11.59% | -10.83% | -10.97% | -15.15% | -7.31% | -3.34% | -0.88% | -6.38% |
| Earnings before Tax (EBT) 1 | -170.8 | -224.9 | -183 | -167.8 | -151.9 | -129.9 | -72.48 | -79.92 | 1.043 | -50.38 | -94.05 | -48.35 | -22.2 | -3.609 | -34.9 |
| Net income 1 | -166.9 | -220.6 | -180.9 | -166.1 | -148.8 | -127.7 | -74.15 | -81.03 | 0.794 | -49.77 | -89.11 | -42.73 | -18.94 | -3.86 | -34.54 |
| Net margin | -36.58% | -46.56% | -37.19% | -31.83% | -28.44% | -23.1% | -12.31% | -13.02% | 0.13% | -7.69% | -14.18% | -6.1% | -2.58% | -0.5% | -4.75% |
| EPS 2 | -0.9700 | -1.280 | -1.040 | -0.9400 | -0.8400 | -0.7200 | -0.4200 | -0.4500 | - | -0.2700 | -0.4919 | -0.2350 | -0.1116 | -0.0225 | -0.2038 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 2/22/22 | 4/26/22 | 8/2/22 | 11/3/22 | 2/21/23 | 5/9/23 | 8/1/23 | 11/1/23 | 2/21/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 504 | - | 1,150 | 1,604 | 1,537 | 1,503 | 1,084 | 678 |
| Net Cash position 1 | - | 497 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -4.176 x | - | -6.114 x | -11.19 x | 7.024 x | 4.503 x | 2.077 x | 0.9657 x |
| Free Cash Flow 1 | -287 | 72.1 | -238 | -438 | 31.9 | 144 | 332 | 533 |
| ROE (net income / shareholders' equity) | -5.66% | -33.2% | -21.2% | -18.4% | -9.08% | -3.57% | 1.79% | 6.46% |
| ROA (Net income/ Total Assets) | -3.34% | -20.1% | -10.3% | -9.16% | -4.42% | -2.65% | 0.05% | 2.5% |
| Assets 1 | 2,515 | 4,215 | 5,805 | 6,810 | 4,614 | 6,057 | 12,280 | 6,577 |
| Book Value Per Share 2 | 15.50 | 18.70 | 19.80 | 17.30 | 17.30 | 17.80 | 19.30 | 21.60 |
| Cash Flow per Share 2 | -0.8800 | 0.8200 | -0.6000 | -1.270 | 0.8700 | 1.410 | 2.190 | 3.320 |
| Capex 1 | 172 | 64.4 | 136 | 214 | 124 | 150 | 153 | 165 |
| Capex / Sales | 19.61% | 4.31% | 7.68% | 10.29% | 4.97% | 5.29% | 4.75% | 4.52% |
| Announcement Date | 2/11/20 | 2/16/21 | 2/22/22 | 2/21/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
58.85
USD
Average target price
89.37
USD
Spread / Average Target
+51.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 377M | |
| +13.32% | 332M |
- Stock Market
- Equities
- EXAS Stock
- Financials Exact Sciences Corporation
